The SOUL trial demonstrated that adult patients with type 2 diabetes and a history of cardiovascular or kidney disease had fewer major adverse cardiovascular events when treated with oral semaglutide compared with placebo. The trial enrolled 9,650 patients aged 50 or older from 33 countries, showing a statistically significant reduction in cardiovascular events and a lower mean HbA1c and weight loss with semaglutide, although associated with more frequent gastrointestinal side effects and higher treatment discontinuation rates.

Source: The New England Journal of Medicine